Clinical impact of body composition phenotypes in patients with COPD: a retrospective analysis

European Journal of Clinical Nutrition

Volumn 73, Issue 11, 2019, Pages 1512-1519

  Machado, Felipe V C ^a   Schneider, Lorena P ^a   Fonseca, Jéssica ^a   Belo, Letícia F ^a   Bonomo, Camila ^a   Morita, Andrea A ^a,b   Furlanetto, Karina C ^a,c   Felcar, Josiane M ^a,c   Rodrigues, Antenor ^a,d   Franssen, Frits M E ^e,f   Spruit, Martijn A ^e,f,g   Pitta, Fabio ^a   Hernandes, Nidia A ^a  

^a STATE UNIVERSITY OF LONDRINA   (Brazil)

^b Hospital Veterinário   (Brazil)

^c Universidade Pitágoras Unopar   (Brazil)

^d Faculdade Pitágoras Campus Metropolitana de Londrina   (Brazil)

^e Department of Research and Education CIRO+ Centre of Expertise for Chronic Organ Failure   (Netherlands)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^g HASSELT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ANXIETY; ARTICLE; BODY COMPOSITION; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DYSPNEA; EXERCISE; FAT MASS; FEMALE; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE STRENGTH; OBESITY; PHENOTYPE; PHYSICAL ACTIVITY; PREVALENCE; REFERENCE VALUE; RETROSPECTIVE STUDY; SARCOPENIA; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGED; BODY COMPOSITION; EXERCISE; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE STRENGTH; OBESITY; PHENOTYPE; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; SARCOPENIA;

EID: 85060085562     PISSN: 09543007     EISSN: 14765640     Source Type: Journal    
DOI: 10.1038/s41430-019-0390-4     Document Type: Article

References (39)

1. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. Available from: http://goldcopd.org. Accessed: 31 July, 2018.
2. Spruit MA, Singh SJ, Garvey C, Zu Wallack R, Niki L, Rochester C, et al. An official American thoracic society/European respiratory society statement: Key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013;188:e-13–64.
3. Schols AM, Ferreira IM, Franssen FM, Gosker HR, Janssens W, Muscaritoli M, et al. Nutritional assessment and therapy in COPD: a European Respiratory Society statement. Eur Respir J. 2014;44:1504–20.
4. Joppa P, Tkacova R, Franssen FME, Hanson C, Rennard SI, Silverman EK, et al. Sarcopenic obesity, functional outcomes, and systemic inflammation in patients with chronic obstructive pulmonary disease. J Am Med Dir Assoc. 2016;17:712–8.
5. Vermeeren MAP, Creutzberg EC, AMWJ Schols, Postma DS, Pieters WR, Roldaan AC, et al. Prevalence of nutritional depletion in a large out-patient population of patients with COPD. Respir Med. 2006;100:1349–55.
6. RJHCG Beijers, van de Bool C, van den Borst B, FME Franssen, EFM Wouters, AMWJ Schols. Normal weight but low muscle mass and abdominally obese: Implications for the cardiometabolic risk profile in chronic obstructive pulmonary disease. J Am Med Dir Assoc. 2017;18:6–11.
7. Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc. 2002;50:889–96.
8. Bjorntorp P, Bray GA, Carroll KK, Chuchalin A, Dietz WH, Ehrlich GE, et al. Obesity: Preventing and managing the global epidemic. WHO Tech. Rep. Ser. 2000;894:i-xii, 1–253.
9. Probst VS, Kovelis D, Hernandes NA, Camillo CA, Cavalheri V, Pitta F. Effects of 2 Exercise Training Programs on Physical Activity in Daily Life in Patients With COPD. Respir Care. 2011;56:1799–807.
10. Felcar JM, Probst VS, de Carvalho DR, Merli MF, Mesquita R, Vidotto LS, et al. Effects of exercise training in water and on land in patients with COPD: a randomised clinical trial. Physiotherapy. (Epub ahead of print). 10.1016/j.physio.2017.10.009.
11. Lukaski HC, Bolonchuk WW, Hall CB, Siders WA. Validation of tetrapolar bioelectrical impedance method to assess human body composition. J Appl Physiol. 1986;60:1327–32.
12. Steiner MC, Barton RL, Singh SJ, Morgan MDL. Bedside methods versus dual energy X-ray absorptiometry for body composition measurement in COPD. Eur Respir J. 2002;19:626–31.
13. Franssen FME, Rutten EPA, Groenen MTJ, Vanfleteren LE, Wouters EFM, Spruit MA. New reference values for body composition by bioelectrical impedance analysis in the general population: Results from the UK biobank. J Am Med Dir Assoc. 2014;15:1–6.
14. Kovelis D, Segretti NO, Probst VS, Lareau SC, Brunetto AF, Pitta F. Validation of the modified pulmonary functional status and dyspnea questionnaire and the medical research council scale for use in Brazilian patients with chronic obstructive pulmonary disease. J Bras Pneumol. 2008;34:1008–18.
15. Pitta F, Probst VS, Kovelis D, Segretti NO, Mt Leoni A, Garod R, et al. [Validation of the Portuguese version of the London Chest Activity of Daily Living Scale (LCADL) in chronic obstructive pulmonary disease patients]. Rev Portu Pneumol. 2008;14:27–47.
16. Botega NJ, Bio MR, Zomignani MA, Garcia C Jr., Pereira WA. [Mood disorders among inpatients in ambulatory and validation of the anxiety and depression scale HAD]. Rev Saude Publica. 1995;29:355–63.
17. Holland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, Saey D, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014;44:1428–46.
18. Britto RR, Probst VS, Dornelas De Andrade AF, Samora GAR, Hernandes NA, Marinho PEM, et al. Reference equations for the six-minute walk distance based on a Brazilian multicenter study. Brazilian J Phys Ther. 2013;17:556–63.
19. Brown LE, Weir JP. ASEP procedures recommendation I: accurate assessment of Muscular strength and Power. J Exerc Physiol. 2001;4:1–21.
20. Black LF, Hyatt RE. Maximal respiratory pressures: normal values and relationship to age and sex. Am Rev Respir Dis. 1969;99:696–702.
21. Neder JA, Andreoni S, Lerario MC, Nery LE. Reference values for lung function tests. II. Maximal respiratory pressures and voluntary ventilation. Braz J Med Biol Res. 1999;32:719–27.
22. van Remoortel H, Raste Y, Louvaris Z, Giavedoni S, Burtin C, Langer D, et al. Validity of six activity monitors in chronic obstructive pulmonary disease: A comparison with indirect calorimetry. PLoS ONE. 2012;7:1–11.
23. Langer D, Gosselink R, Sena R, Burtin C, Decramer M, Troosters T. Validation of two activity monitors in patients with COPD. Thorax. 2009;64:641–2.
24. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171:972–7.
25. Patel SA, Benzo RP, Slivka WA, Sciurba FC. Activity monitoring and energy expenditure in COPD Patients: A validation study. COPD. J Chronic Obstr Pulm Dis. 2007;4:107–12.
26. Mesquita R, Meijer K, Pitta F, Azcuna H, Goertz YMJ, Essers JMN, et al. Changes in physical activity and sedentary behaviour following pulmonary rehabilitation in patients with COPD. Respir Med. 2017;126:122–9.
27. Demeyer H, Burtin C, Van Remoortel H, Hornikx M, Langer D, Decramer M, et al. Standardizing the analysis of physical activity in patients with COPD following a pulmonary rehabilitation program. Chest. 2014;146:318–27.
28. Ainsworth BE, Haskell WL, Herrmann SD, Meckes N, Bassett DR Jr., Tudor-Locke C, et al. 2011 Compendium of Physical Activities: a second update of codes and MET values. Med Sci Sports Exerc. 2011;43:1575–81.
29. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA. et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:1005–12.
30. Van De Bool C, Rutten EPA, Franssen FME, Wouters EFM, Schols AMWJ. Antagonistic implications of sarcopenia and abdominal obesity on physical performance in COPD. Eur Respir J. 2015;46:336–45.
31. Ischaki E, Papatheodorou G, Gaki E, Papa I, Koulouris N, Loukides S. Body mass and fat-free mass indices in COPD. Chest. 2007;132:164–9.
32. MPKJ Engelen, Schols AMWJ, Does JD, Wouters EFM. Skeletal muscle weakness is associated with wasting of extremity fat-free mass but not with airflow obstruction in patients with. Am J Clin Nutr. 2000;71:733–8.
33. Sabino PG, Silva BM, Brunetto AF. Nutritional status is related to fat-free mass, exercise capacity and inspiratory strength in severe chronic obstructive pulmonary disease patients. Clinics. 2010;65:599–605.
34. Luo y, Zhou L, Li Y, Guo S, Li X, Zheng J, et al. Fat-free mass index for evaluating the nutritional status and disease severity in COPD. Respir Care. 2016;61:580–8.
35. Ora J, Laveneziana P, Wadell K, Preston M, Webb KA, O’Donnell DE. Effect of obesity on respiratory mechanics during rest and exercise in COPD. J Appl Physiol. 2011;111:10–9.
36. Kyle UG, Schutz Y, Dupertuis YM, Pichard C. Body composition interpretation: Contributions of the fat-free mass index and the body fat mass index. Nutrition. 2003;19:597–604.
37. Maltais F, Decramer M, Casaburi R, Barreiro E, Burelle Y, Debiga R, et al. An official American thoracic society/european respiratory society statement: Update on limb muscle dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014;189:15–62.
38. Watz H, Pitta F, Rochester CL, Garcia-Aymerich J, ZuWallack R, Troosters T, et al. An official European respiratory society statement on physical activity in COPD. Eur Respir J. 2014;44:1521–37.
39. Kyle UG, Bosaeus I, De Lorenzo AD, Deurenberg P, Elia M, Gómez JM, et al. Bioelectrical impedance analysis - Part I: Review of principles and methods. Clin Nutr. 2004;23:1226–43.